Symposium 25: The NLRP3 inflammasome, a rising star in cardiovascular pharmacology
Tracks
Track 1
| Friday, July 17, 2026 |
| 11:15 AM - 1:15 PM |
Details
This symposium is centered around the NLRP3 inflammasome and it addresses novel findings that underpin a promising role for this protein complex of the innate immune system and its end-products, namely interleukin-1beta, as drug targets for cardiovascular (CV) diseases. The cutting edge topics of the symposium explore cross-organ brain-heart interactions in the context of a true non-infectious pandemic such is obesity or vascular cell senescence and inflammaging as drivers of CV disease in a worldwide aging population. The NLRP3 inflammasome is also regarded as a valuable target in cardiac non-muscle cells, such are cardiac fibroblasts, as drivers of heart diseases as well as in the context of hemostatic and platelet disorders. The development of novel NLRP3 inhibitors based on gasotransmitters release will also be addressed. Overall, the symposium brings variety and innovation on a rising pharmacological target for a cluster of diseases that constitute a global health challenge.
Speaker
Dr Ramaroson Andriantsitohaina
INSERM U1046 - UMR CNRS 9214 - University Montpellier
Hypothalamic inflammasome controls atrial fibrillation triggered by obesity
Biography
Since 2004, R Andriantsitohaina (Director of Research INSERM 244 publications, H index 60) is involved in the isolation, characterization and bioactions of EVs from different cohort (sepsis, Crohn, obstructive sleep apnea, preeclampsia, metabolic syndrome, obesity, diabetes). He is internationally recognized in the field of EVs and cardiovascular and metabolic diseases: (i) Demonstration of a correlation between the increase of total circulating EVs with some EV subsets, endothelial dysfunction, vascular hyporeactivity and in the development of atherosclerosis; (ii) EVs as potential biomarkers and biological vectors of obstructive sleep apnea-associated vascular impairment by promoting endothelial dysfunction and modifying its secretome, inflammation and vascular hyper-reactivity. Also, he has developed therapeutic approaches using EVs: (i) EVs bearing sonic hedgehog are cardioprotective in heart ischemia/reperfusion; (ii) sEVs can be used for the selective delivery of therapeutic agents from the blood to the brain to target neurons in the hypothalamus extending this exciting nanobiomedecine approach to potential applications for the treatment of obesity.
Prof Guillermo Díaz-Araya
Department of Chemical Pharmacology and Toxicology. Faculty of Chemistry and Pharmaceutical Sciences. University of Chil
Cardiac fibroblasts as drivers of inflammation and heart disease
Biography
Session chair
Ramaroson Andriantsitohaina
INSERM U1046 - UMR CNRS 9214 - University Montpellier
Concepción Peiró
Department Of Pharmacology, Universidad Autónoma De Madrid
